Literature DB >> 14600842

DB-289 Immtech International.

Clive Yeates1.   

Abstract

DB-289, an oral diamidoxime prodrug of DB-75 from the University of North Carolina, Georgia State University, Auburn University and Duke University, is being developed by Immtech International as a potential treatment for Pneumocystis carinii pneumonia (PCP), tuberculosis, trypanosomiasis and malaria.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14600842

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  8 in total

1.  CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime].

Authors:  Michael Zhuo Wang; Janelle Y Saulter; Etsuko Usuki; Yen-Ling Cheung; Michael Hall; Arlene S Bridges; Greg Loewen; Oliver T Parkinson; Chad E Stephens; James L Allen; Darryl C Zeldin; David W Boykin; Richard R Tidwell; Andrew Parkinson; Mary F Paine; James Edwin Hall
Journal:  Drug Metab Dispos       Date:  2006-09-22       Impact factor: 3.922

2.  T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena.

Authors:  Eio Yamada; Hiroshi Nishikawa; Nobuhiko Nomura; Junichi Mitsuyama
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites.

Authors:  Myaing M Nyunt; Craig W Hendrix; Rahul P Bakshi; Nirbhay Kumar; Theresa A Shapiro
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

Review 4.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

5.  In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.

Authors:  Junichi Mitsuyama; Nobuhiko Nomura; Kyoko Hashimoto; Eio Yamada; Hiroshi Nishikawa; Makoto Kaeriyama; Akiko Kimura; Yozo Todo; Hirokazu Narita
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

6.  T-2307 causes collapse of mitochondrial membrane potential in yeast.

Authors:  Tatsuya Shibata; Toshinari Takahashi; Eio Yamada; Akiko Kimura; Hiroshi Nishikawa; Hiroyoshi Hayakawa; Nobuhiko Nomura; Junichi Mitsuyama
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

7.  Neglected disease - african sleeping sickness: recent synthetic and modeling advances.

Authors:  Sarvesh K Paliwal; Ankita Narayan Verma; Shailendra Paliwal
Journal:  Sci Pharm       Date:  2011-05-10

Review 8.  Targeting Transcription Factors for Cancer Treatment.

Authors:  Mélanie Lambert; Samy Jambon; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.